Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.80B | 7.83B | 5.22B | 7.09B | 5.15B | 5.61B |
Gross Profit | 1.94B | 1.45B | 1.29B | 2.11B | 1.81B | 1.81B |
EBITDA | 1.38B | 1.45B | 593.89M | 1.21B | 1.20B | 1.25B |
Net Income | 660.99M | 691.36M | -70.59M | 498.26M | 622.20M | 625.27M |
Balance Sheet | ||||||
Total Assets | 0.00 | 11.53B | 8.80B | 10.34B | 8.60B | 8.12B |
Cash, Cash Equivalents and Short-Term Investments | 90.66M | 415.86M | 140.71M | 361.16M | 465.83M | 404.23M |
Total Debt | 0.00 | 3.11B | 2.54B | 2.81B | 2.63B | 2.55B |
Total Liabilities | -5.64B | 5.13B | 4.19B | 4.98B | 3.89B | 4.02B |
Stockholders Equity | 5.64B | 6.40B | 4.61B | 5.36B | 4.70B | 4.11B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -588.57M | -74.71M | -20.35M | 129.86M | -612.96M |
Operating Cash Flow | 0.00 | 645.23M | 224.50M | 501.25M | 402.34M | 904.53M |
Investing Cash Flow | 0.00 | -1.24B | -296.86M | -520.72M | -271.53M | -1.52B |
Financing Cash Flow | 0.00 | 644.32M | -319.69M | 306.79M | -69.21M | 920.18M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | ₹26.58B | 28.46 | 0.40% | 2.12% | -25.99% | ||
61 Neutral | ₹30.44B | 141.32 | ― | -7.29% | ― | ||
56 Neutral | ₹20.78B | 27.48 | 0.17% | 10.29% | 26.79% | ||
52 Neutral | ₹13.46B | 29.68 | 0.24% | 17.50% | ― | ||
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
47 Neutral | ₹25.24B | 96.22 | 0.54% | -8.28% | -246.17% | ||
― | ₹37.09B | 38.87 | 0.79% | ― | ― |
SMS Pharmaceuticals Limited announced the transfer of shares to the Investor Education Protection Fund (IEPF) due to unpaid or unclaimed dividends from the financial year 2017-2018. This move, communicated through newspaper advertisements in Financial Express and Nava Telangana, is part of the company’s compliance with SEBI regulations, ensuring transparency and adherence to financial obligations.